Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases its August 2019 Corporate Presentation ahead of Australian and U.S. roadshows.
The Presentation contains an update on recent studies showing Veyonda® to be a STING activator, and the impact this is expected to have on the Company’s clinical development program and commercial opportunity.
For further information download the attached PDF:
Download this document
